Latest Life Sciences News

EZZ Life Science has inked a three-year distribution deal with ROFA Enterprises, marking a significant step into Southeast Asia’s booming health market. The agreement guarantees at least A$21 million in sales across Thailand, Vietnam, and Singapore.

Wellnex Life Limited has had its trading suspension lifted following its response to ASX queries related to a recent shareholder letter, reopening market access to its shares.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.

ALS Limited reported a 16% revenue increase to nearly $3 billion in FY2025, driven by acquisitions and organic growth, while underlying net profit after tax dipped slightly. The company announced a $350 million equity raise to fund expansion and sustainability initiatives.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.

Microba Life Sciences reveals breakthrough data showing its MetaPanel™ test detects elusive gastrointestinal pathogens in 20% of chronic cases, enabling targeted treatment and complete symptom resolution.

Lendlease has partnered with The Crown Estate to create a 50/50 joint venture aimed at accelerating capital recycling of over $300 million through UK commercial and residential developments. The deal also includes a $1.2 billion Australian office investment mandate, boosting Lendlease’s funds under management to $20 billion.

Microba Life Sciences reveals preliminary data from over 4,600 MetaXplore GI Plus tests showing significant clinical findings in the majority of patients, with two-thirds reporting symptom improvements following test-guided care.